Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 7, 2014, Pages 1054-1065

  Perzborn, E ^a   Heitmeier, S ^a   Buetehorn, U ^a   Laux, V ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Dabigatran; Hypercoagulability; Melagatran; Rivaroxaban; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; DABIGATRAN; MELAGATRAN; RECOMBINANT THROMBOMODULIN; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR; ANTITHROMBIN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PROTEIN C; PROTHROMBIN; THIOPHENE DERIVATIVE; THROMBOMODULIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETER; HUMAN; HYPERCOAGULABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBIN TIME; THROMBOCYTE COUNT; ANIMAL; BLOOD CLOTTING; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; PLASMA; THROMBOCYTE; THROMBOELASTOGRAPHY; THROMBOPHILIA; WISTAR RAT;

ANIMALS; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; BLOOD PLATELETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA INHIBITORS; HUMANS; MALE; MORPHOLINES; PLASMA; PLATELET COUNT; PROTEIN C; PROTHROMBIN; RATS; RATS, WISTAR; RIVAROXABAN; THIOPHENES; THROMBELASTOGRAPHY; THROMBIN; THROMBOMODULIN; THROMBOPHILIA; THROMBOPLASTIN;

EID: 84904302336     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12591     Document Type: Article

References (28)

1. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62: 41-57.
2. Executive Steering Committee of behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8.
3. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
4. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125: 669-76.
5. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-18.
6. Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2012; 2: e001592.
7. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-9.
8. Ruyi H. Integrated executive summary of FDA review for NDA 21-686 Exanta (ximelagatran). 2004. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_03_FDA-Backgrounder-Execsummaryredacted.pdf. Accessed 24 March 2014.
9. Eikelboom JW, Weitz JI. Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol 2012; 9: 260-2.
10. Furugohri T, Shiozaki Y, Muramatsu S, Honda Y, Matsumoto C, Isobe K, Sugiyama N. Different antithrombotic properties of Factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur J Pharmacol 2005; 514: 35-42.
11. Furugohri T, Sugiyama N, Morishima Y, Shibano T. Antithrombin-independent thrombin inhibitors, but not direct Factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 2011; 106: 1076-83.
12. Furugohri T, Fukuda T, Tsuji N, Kita A, Morishima Y, Shibano T. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct Factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats. Eur J Pharmacol 2012; 686: 74-80.
13. Mattsson C, Menschik-Lundin A, Nylander S, Gyzander E, Deinum J. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb Res 2001; 104: 475-86.
14. Linder R, Frebelius S, Grip L, Swedenborg J. The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin. Thromb Res 2003; 110: 221-6.
15. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
16. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565-8.
17. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
18. Depasse F, Busson J, Mnich J, Le Flem L, Gerotziafas GT, Samama MM. Effect of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro. J Thromb Haemost 2005; 3(Suppl 1): Abstract P1104.
19. Wagenvoord RJ, Deinum J, Elg M, Hemker HC. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost 2010; 8: 1281-9.
20. Winquist J, Geschwindner S, Xue Y, Gustavsson L, Musil D, Deinum J, Danielson UH. Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors. Biochemistry 2013; 52: 613-26.
21. Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-7.
22. Hemker HC, Giesen P, al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
23. Esmon CT. What did we learn from new oral anticoagulant treatment? Thromb Res 2012; 130(Suppl 1): S41-3.
24. Christersson C, Oldgren J, Wallentin L, Siegbahn A. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med 2011; 270: 215-23.
25. Ellinghaus P, Laux V, Perzborn E. Effect of rivaroxaban on thrombin-induced pro-inflammatory gene expression in human umbilical vein endothelial cells. J Thromb Haemost 2011; 9: 491, Abstract P-TU-577.
26. Cullberg M, Eriksson UG, Wåhlander K, Eriksson H, Schulman S, Karlsson MO. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther 2005; 77: 279-90.
27. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-502.
28. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97: 1685-8.